Efficacy of sublingual immunotherapy for house dust mite allergic rhinitis

Eur Arch Otorhinolaryngol. 2015 Nov;272(11):3341-6. doi: 10.1007/s00405-014-3444-1. Epub 2014 Dec 17.


In the present study, we investigated the outcomes of sublingual immunotherapy (SLIT) in house dust mite-induced allergic rhinitis (HDM-AR) patients. In this prospective, multicentric study, 186 patients with AR who had positive skin prick test results for HDMs were included. The patients were administered SLIT using Staloral 300 for 1 year. Evaluation of the patients regarding symptom scores, clinical findings and Rhinitis Quality of Life Questionnaire (RQLQ) scores was performed at baseline, and then at 6 and 12 months of therapy. Our results showed that, for all of the evaluated items (symptom scores, clinical findings and RQLQ scores), 12-month values were significantly lower than those at 6 months and baseline. Similarly, 6-month values were significantly lower than those at baseline. There were no complications in any of our patients. SLIT for HDM-AR is a treatment modality that can be used safely. We obtained better results than expected, and the treatment showed a positive psychological effect; the patients believed that SLIT was the final step of treatment and, which made them feel better.

Keywords: Allergic rhinitis (AR); House dust mite (HDM); Rhinitis Quality of Life Questionnaire (RQLQ); Sublingual immunotherapy (SLIT).

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Animals
  • Antigens, Dermatophagoides / immunology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Pyroglyphidae / immunology*
  • Quality of Life
  • Rhinitis, Allergic, Perennial / diagnosis
  • Rhinitis, Allergic, Perennial / immunology
  • Rhinitis, Allergic, Perennial / therapy*
  • Sublingual Immunotherapy*
  • Surveys and Questionnaires
  • Treatment Outcome
  • Young Adult


  • Antigens, Dermatophagoides